Market research
RAC.AU Race Oncology Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 412M
- P/E ratio
- Not available
- Analyst target
- 7.46
- Dividend yield
- Not available
- Beta
- 0.82
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000RAC3
- Market cap
- 412M
- P/E ratio
- Not available
- Analyst target
- 7.46
- Dividend yield
- Not available
- Beta
- 0.82
About
About Race Oncology Limited
Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across various oncology indications with Phase 3 clinical programs in acute myeloid leukaemia, Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin. It has collaborations with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. The company was formerly known as Race Oncology Ltd and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RAC.AU discussion.
5 years, 5 months ago
Race Oncology Limited is currently in a long term uptrend where the price is trading 39.3% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Race Oncology Limited's total revenue rose by 273.9% to $11K since the same quarter in the previous year.
Its net income has dropped by 37.1% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 39.0% to $-592K since the same quarter in the previous year.
Based on the above factors, Race Oncology Limited gets an overall score of 3/5.